In February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of my favorite stocks. Shares have jumped by more than 20,000% since then.

I believe we are about to do it again with this new AI project called Stargate

Christian Waage Biography and Net Worth

Director of Heron Therapeutics

Christian Waage has served as a director of Heron since 2016. Mr. Waage has more than 15 years of regulatory, legal and financial transaction experience primarily in the biotechnology industry. Since 2017, he has served as Executive Vice President and General Counsel of Gossamer Bio, Inc., a publicly traded biotechnology company. From 2013 to 2016, Mr. Waage held various positions at Receptos, Inc., a wholly owned subsidiary of Celgene Corporation, most recently serving as Managing Director. Prior to its acquisition by Celgene Corporation in 2015, he served as Senior Vice President and General Counsel of Receptos, Inc. From 2012 through its acquisition by Vista Equity Partners Management, LLC in 2013, Mr. Waage served as Vice President, General Counsel and Corporate Secretary at Websense, Inc. From 2008 through its acquisition by AstraZeneca PLC in 2012, he served as Vice President, General Counsel and Corporate Secretary of Ardea Biosciences, Inc. Prior to 2008, Mr. Waage served as a partner at DLA Piper LLP. He received a J.D. from the University of San Diego School of Law and a B.A. degree in economics from the University of California, San Diego. The Board has concluded that Mr. Waage should serve as a director based on his experience in regulatory, legal and finance matters.

What is Christian Waage's net worth?: The estimated net worth of Christian Waage is at least $34,655.16 as of March 20th, 2023. Mr. Waage owns 32,388 shares of Heron Therapeutics stock worth more than $34,655 as of November 23rd. This net worth estimate does not reflect any other investments that Mr. Waage may own. Learn More about Christian Waage's net worth.
How do I contact Christian Waage?: The corporate mailing address for Mr. Waage and other Heron Therapeutics executives is 4242 CAMPUS POINT COURT SUITE 200, SAN DIEGO CA, 92121. Heron Therapeutics can also be reached via phone at (858) 251-4400 and via email at [email protected]. Learn More on Christian Waage's contact information.
Has Christian Waage been buying or selling shares of Heron Therapeutics?: Christian Waage has not been actively trading shares of Heron Therapeutics within the last three months. Most recently, Waage Christian sold 300 shares of the business's stock in a transaction on Tuesday, December 21st. The shares were sold at an average price of $9.73, for a transaction totalling $2,919.00. Learn More on Christian Waage's trading history.
Who are Heron Therapeutics' active insiders?: Heron Therapeutics' insider roster includes Craig Johnson (Director), Kimberly Manhard (EVP), and Christian Waage (Director). Learn More on Heron Therapeutics' active insiders.

Christian Waage Insider Trading History at Heron Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
12/21/2021	Sell	300	$9.73	$2,919.00
9/21/2021	Sell	300	$12.31	$3,693.00
6/21/2021	Sell	300	$15.20	$4,560.00	3,800
4/15/2021	Sell	300	$17.51	$5,253.00	4,100
5/15/2019	Buy	1,400	$18.04	$25,256.00	1,400

Christian Waage Buying and Selling Activity at Heron Therapeutics

Heron Therapeutics Company Overview

Heron Therapeutics, Inc., a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; and APONVIE, an intravenous formulation of a substance P/neurokinin-1 receptor antagonist indicated for the prevention of postoperative nausea and vomiting in adults. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in San Diego, California.

Today's Range

Now: $1.07

$1.06

$1.10

50 Day Range

MA: $1.75

$1.06

$2.12

2 Week Range

Now: $1.07

$1.04

$3.93

Volume

1,334,824 shs

Average Volume

2,401,417 shs

Market Capitalization

$162.75 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.81

Bill Gates’s Next Big AI Bet: Stargate

From Brownstone Research | Ad